Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
40 participants
INTERVENTIONAL
2025-05-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Breast cancer is the most diagnosed cancer amongst UK women, with incidence rates increasing by around a quarter since the early 1990s. It accounts for 30% of all female diagnosed cancers and causes around 11,500 deaths in the UK annually. Early detection is key as stage at diagnosis is the most important predictor of health outcome and most cancers are diagnosed after symptomatic patients see their GP. This highlights the pivotal role of primary care with managing breast-related abnormalities in a timely and appropriate manner. Little is currently known about the research area, particularly from a qualitative standpoint.
Adult females who have been referred to secondary care by their GP because of a breast health concern will be eligible to take part in the study. Participants will mainly be recruited through the Nottingham Breast Institute, East Midlands GP surgeries, and the study funder's digital/online influencer channels. Participants will be involved in semi-structured interviews or focus groups, with the data collection phase expected to take around six months. The study is funded by breast health awareness charity, Coppafeel!.
The findings of a systematic review and analysis of breast cancer-related online support group messages, focusing on the experiences relating to women seeing their GP with breast-health issues (also being undertaken by the researcher), will also be used to triangulate and inform study findings.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Promoting Breast Cancer Screening in Non-adherent Women
NCT01332032
Breast Cancer Screening Uptake: a Randomized Controlled Trial Assessing the Effect of a Decisional Aid
NCT05607849
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
NCT06780176
The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach
NCT00393406
Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care
NCT05400941
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives:
* To find out about the factors women perceive as those which hindered and/or facilitated participants' referral to a breast clinic for further investigation, and how and why the female patients believe these occurred.
* To look at improvements/changes the participants believe could be implemented to improve the related management of their health, particularly from a medical education perspective.
Settings:
Interviews/focus groups will be held online wherever possible using the following to reach potential participants:
* New referral clinics at the Nottingham Breast Institute at Nottingham City Hospital
* NIHR 'research initiative site' GP practices across the East Midlands which elect to get involved as participant identification centres; and
* The funder's (CoppaFeel!) digital communications channels and those of its ambassadors/social media influencers to reach potential participants.
Number of participants:
Up to 40 participants may be recruited but the concept of information power will be used to inform actual sample size. The participants will be women who have been to see their GP with breast-related health issues/symptoms.
Interventions:
* Requesting responses to related medical history/status and demographic questions in advance of the related substantive interview or focus group discussion (once per participant) - approx. 30 mins
* One online semi-structured interview or focus group discussion per participant - approx. 1 hour.
Duration of study:
* Overall: six months (to start soon as all necessary approvals are in place)
* Per participant: up to three months.
Method of analysis:
Data collected will be examined using inductive thematic analysis. This analytical approach allows themes, patterns and meanings to be generated from the data, and in the process, help identify factors which participants perceive as helping or hindering their breast referral to secondary care among patients and primary care healthcare professionals; and why, and how, these occurred.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
Participants will either be involved in an online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option.
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Data collection
Semi-structured interview or focus group discussion.
Semi-structured interview/focus group discussion
All participants will be asked via email for their medical history/status and demographic information.
Participants will either be involved in online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Semi-structured interview/focus group discussion
All participants will be asked via email for their medical history/status and demographic information.
Participants will either be involved in online semi-structured interview or focus group discussion (FGD). Note: they may allocated to a FGD where they share common characteristics with other participants (eg, they are younger women or presented at their GP practice with non-lump symptoms). However, if the participants prefer to be interviewed instead, the student will accommodate this option.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 years and over (no upper age limit)
* Have/had breast-related health concerns regardless of breast cancer diagnosis
* Have presented their symptoms initially in a primary care setting rather than having been alerted to potential issues during routine breast screening
* Been referred from primary care within the previous year
* Be using the NHS healthcare system in either England or Wales.
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute for Health Research, United Kingdom
OTHER_GOV
CoppaFeel
UNKNOWN
University of Nottingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Nottingham
Nottingham, Nottinghamshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRAS project ID: 334924
Identifier Type: OTHER
Identifier Source: secondary_id
Sponsor ref 24068
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.